Camelia Frantz1, Agnes Portier2, Adrien Etcheto3, Dominique Monnet4, Antoine Brezin4, Fanny Roure1, Muriel Elhai1, Vincent Burki1, Isabelle Fabreguet1, Eugenie Koumakis1, Judith Payet1, Laure Gossec5, Maxime Dougados6, Anna Molto7. 1. Rheumatology B Department, Cochin Hospital, Paris Descartes University, Paris, France. 2. Rheumatology Department, Saint-Joseph Hospital, Paris, France. 3. INSERM (U1153): Clinical Epidemiology and Biostatistics-PRES Sorbonne Paris-Cité, France. 4. Ophthalmology Department, Cochin Hospital, Paris Descartes University, Paris, France. 5. Department of Rheumatology, Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Paris, France. 6. Rheumatology B Department, Cochin Hospital, Paris Descartes University, Paris, and INSERM (U1153): Clinical Epidemiology and Biostatistics-PRES Sorbonne Paris-Cité, France. 7. Rheumatology B Department, Cochin Hospital, Paris Descartes University, Paris, and INSERM (U1153): Clinical Epidemiology and Biostatistics-PRES Sorbonne Paris-Cité, France. anna.molto@aphp.fr.
Abstract
OBJECTIVES: To assess the cumulative incidence of uveitis in spondyloarthritis (SpA) and its associated factors and to evaluate the effect of DMARD treatment on uveitis in a real-life setting. METHODS: A cross-sectional monocentric observational study (COSPA) was conducted. Patients with definite SpA underwent a face-to-face interview. General data and specific data concerning uveitis were collected. Cumulative incidence of uveitis flares was estimated by Kaplan-Meier survival curves. Factors associated with uveitis were determined by Cox analysis. Treatment effectiveness was evaluated by comparing the number of uveitis flares before/after treatment using Wilcoxon test. RESULTS: In total, 301 patients were included, 186 (61.8%) were men, with mean age and disease duration of 44.8 (±13.6) and 16.8 (±11.9) years, respectively. Among them, 82 (27.2%) had at least one uveitis flare. Prevalence of uveitis at the time of SpA diagnosis was 11.5 % (±1.9%) and increased over time to reach 39.3% (±4.1%) 20 years after diagnosis. HLA B27 positivity and heel pain were independently associated with uveitis (HR [IC 95%] = 4.5 [1.3-15.2] and 1.8 [1.1-2.9], respectively). A significant reduction in the number of uveitis before/after treatment was observed in patients treated with anti TNF monoclonal antibodies (n=27), (1.83 (±4.03) vs. 0.41 (±1.22), p=0.002), whereas it was not with etanercept (n=19), (0.44 (±0.70) and 0.79 (±1.36), p=NS). CONCLUSIONS: Prevalence of uveitis in SpA seems to increase with disease duration and seems more likely to appear with HLA B27 positivity and heel pain. Anti-TNF monoclonal antibodies seemed to be more effective in the reduction of uveitis flares.
OBJECTIVES: To assess the cumulative incidence of uveitis in spondyloarthritis (SpA) and its associated factors and to evaluate the effect of DMARD treatment on uveitis in a real-life setting. METHODS: A cross-sectional monocentric observational study (COSPA) was conducted. Patients with definite SpA underwent a face-to-face interview. General data and specific data concerning uveitis were collected. Cumulative incidence of uveitis flares was estimated by Kaplan-Meier survival curves. Factors associated with uveitis were determined by Cox analysis. Treatment effectiveness was evaluated by comparing the number of uveitis flares before/after treatment using Wilcoxon test. RESULTS: In total, 301 patients were included, 186 (61.8%) were men, with mean age and disease duration of 44.8 (±13.6) and 16.8 (±11.9) years, respectively. Among them, 82 (27.2%) had at least one uveitis flare. Prevalence of uveitis at the time of SpA diagnosis was 11.5 % (±1.9%) and increased over time to reach 39.3% (±4.1%) 20 years after diagnosis. HLA B27 positivity and heel pain were independently associated with uveitis (HR [IC 95%] = 4.5 [1.3-15.2] and 1.8 [1.1-2.9], respectively). A significant reduction in the number of uveitis before/after treatment was observed in patients treated with anti TNF monoclonal antibodies (n=27), (1.83 (±4.03) vs. 0.41 (±1.22), p=0.002), whereas it was not with etanercept (n=19), (0.44 (±0.70) and 0.79 (±1.36), p=NS). CONCLUSIONS: Prevalence of uveitis in SpA seems to increase with disease duration and seems more likely to appear with HLA B27 positivity and heel pain. Anti-TNF monoclonal antibodies seemed to be more effective in the reduction of uveitis flares.
Authors: Irene E van der Horst-Bruinsma; Rianne E van Bentum; Frank D Verbraak; Atul Deodhar; Thomas Rath; Bengt Hoepken; Oscar Irvin-Sellers; Karen Thomas; Lars Bauer; Martin Rudwaleit Journal: Ther Adv Musculoskelet Dis Date: 2021-03-29 Impact factor: 5.346
Authors: Irene E van der Horst-Bruinsma; Philip C Robinson; Ennio G Favalli; Frank D Verbraak; Mindy Kim; Thomas Kumke; Lars Bauer; Bengt Hoepken; Atul Deodhar Journal: Rheumatol Ther Date: 2022-09-30